BR0317134A - Composições e métodos de liberação de agentes farmacológicos - Google Patents
Composições e métodos de liberação de agentes farmacológicosInfo
- Publication number
- BR0317134A BR0317134A BR0317134-5A BR0317134A BR0317134A BR 0317134 A BR0317134 A BR 0317134A BR 0317134 A BR0317134 A BR 0317134A BR 0317134 A BR0317134 A BR 0317134A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- pharmaceutical composition
- pharmacological agent
- release compositions
- agent release
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000002831 pharmacologic agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 102000008100 Human Serum Albumin Human genes 0.000 abstract 2
- 108091006905 Human Serum Albumin Proteins 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 abstract 1
- 229960000958 deferoxamine Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/701—Integrated with dissimilar structures on a common substrate
- Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
- Y10S977/705—Protein or peptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
- Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/908—Mechanical repair performed/surgical
- Y10S977/911—Cancer cell destruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43231702P | 2002-12-09 | 2002-12-09 | |
US22551903A | 2003-12-03 | 2003-12-03 | |
US22554903A | 2003-12-04 | 2003-12-04 | |
US22558503A | 2003-12-05 | 2003-12-05 | |
PCT/US2003/038941 WO2004052401A2 (en) | 2002-12-09 | 2003-12-09 | Compositions and methods of delivery of pharmacological agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0317134A true BR0317134A (pt) | 2005-11-22 |
Family
ID=32512525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317134-5A BR0317134A (pt) | 2002-12-09 | 2003-12-09 | Composições e métodos de liberação de agentes farmacológicos |
Country Status (6)
Country | Link |
---|---|
KR (8) | KR20110079741A (pt) |
BR (1) | BR0317134A (pt) |
MX (1) | MXPA05006169A (pt) |
NZ (1) | NZ541142A (pt) |
PT (1) | PT1585548T (pt) |
WO (1) | WO2004052401A2 (pt) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
TR200502189T1 (tr) | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US8476010B2 (en) | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
HUE038768T2 (hu) * | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
JP2008530236A (ja) * | 2005-02-18 | 2008-08-07 | アブラクシス バイオサイエンス、インコーポレイテッド | 虚血障害用の、2,6−ジイソプロピルフェノール及び類似体の組成物、使用及び調製方法。 |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
CN100358513C (zh) * | 2005-04-07 | 2008-01-02 | 常州市第四制药厂有限公司 | 一种丙泊酚注射液的制备工艺 |
CN101291658B (zh) * | 2005-08-31 | 2014-04-16 | 阿布拉科斯生物科学有限公司 | 用于制备稳定性增加的水难溶性药物的组合物和方法 |
TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
CA2626016A1 (en) * | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
US20090258053A1 (en) * | 2006-08-23 | 2009-10-15 | Blue Medical Deevices Bv | Medical stent provided with a combination of melatonin and paclitaxel |
CN101568332A (zh) * | 2006-08-31 | 2009-10-28 | 阿布拉科斯生物科学公司 | 抑制血管生成及治疗血管生成相关疾病的方法 |
WO2015081096A2 (en) * | 2013-11-26 | 2015-06-04 | The Brigham And Women's Hospital, Inc. | Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery |
SI2117520T1 (sl) | 2006-12-14 | 2019-01-31 | Abraxis Bioscience, Llc | Zdravljenje raka dojk glede na status hormonskih receptorjev z nano delci, ki zajemajo taksan |
MX2009009537A (es) * | 2007-03-07 | 2009-09-16 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
EP2818550B1 (en) | 2007-05-11 | 2016-12-28 | Adynxx, Inc. | Gene expression and pain |
WO2008150532A1 (en) | 2007-06-01 | 2008-12-11 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
BRPI0907595A2 (pt) * | 2008-02-19 | 2015-07-21 | Novartis Ag | Combinação de um quelante de ferro e um imunossupressor e uso dos mesmos |
PL2291523T3 (pl) * | 2008-06-24 | 2015-05-29 | Csl Behring Gmbh | Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo |
DK2419732T3 (da) | 2009-04-15 | 2019-12-16 | Abraxis Bioscience Llc | Prionfrie nanopartikelsammensætninger og fremgangsmåder |
HUE027749T2 (en) | 2010-03-26 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating hepatocellular carcinoma |
RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
NZ602635A (en) | 2010-03-29 | 2014-12-24 | Abraxis Bioscience Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
US9399071B2 (en) | 2010-06-04 | 2016-07-26 | Abraxis Bioscience, Llc | Methods of treatment of pancreatic cancer |
US11326150B2 (en) * | 2011-09-27 | 2022-05-10 | Public University Corporation Yokohama City University | Method for producing tissue and organ |
PL2790675T3 (pl) | 2011-12-14 | 2019-12-31 | Abraxis Bioscience, Llc | Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek |
BR112014027653A2 (pt) * | 2012-05-10 | 2017-08-08 | Adynxx Inc | formulações para a liberação dos ingredientes ativos |
US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
CN105228612A (zh) | 2013-03-12 | 2016-01-06 | 阿布拉科斯生物科学有限公司 | 治疗肺癌的方法 |
ES2881851T3 (es) | 2013-03-14 | 2021-11-30 | Abraxis Bioscience Llc | Métodos para tratar el cáncer de vejiga |
ES2657291T3 (es) | 2013-04-22 | 2018-03-02 | Csl Ltd. | Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro |
WO2016025829A1 (en) | 2014-08-15 | 2016-02-18 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
PL3313401T3 (pl) | 2015-06-29 | 2022-02-07 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające sirolimus i albuminę do stosowania w leczeniu nowotworów z komórek epitelioidnych |
CN112188892A (zh) | 2018-03-20 | 2021-01-05 | 阿布拉科斯生物科学有限公司 | 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法 |
MX2022004989A (es) | 2019-10-28 | 2022-07-21 | Abraxis Bioscience Llc | Composiciones farmaceuticas de albumina y rapamicina. |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56125317A (en) * | 1980-03-08 | 1981-10-01 | Nippon Mejifuijitsukusu Kk | Stable radioactive diagnosticum with radioactive metallic mark |
JPS59199636A (ja) * | 1983-04-26 | 1984-11-12 | Nippon Mejifuijitsukusu Kk | 放射性診断剤 |
EP0227593A1 (en) * | 1985-11-25 | 1987-07-01 | The Hospital For Sick Children | Use of chelating agents |
WO1992007259A1 (en) * | 1990-10-16 | 1992-04-30 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
KR19990063632A (ko) * | 1995-09-21 | 1999-07-26 | 디 헤이쓰, 산드라 우드 | 약물 운송용 트란스사이토시스 매개체 및 상승제 |
DE19636889A1 (de) * | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
US5990153A (en) * | 1997-05-05 | 1999-11-23 | Wood; John G. | Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury |
FR2775900A1 (fr) * | 1998-03-10 | 1999-09-17 | Charles Dumontet | Compositions medicamenteuses contenant de la deferoxamine pour la prevention des toxicites hematopoietique et tissulaire des anthracyclines et de leurs derives |
WO2000023117A1 (en) * | 1998-10-16 | 2000-04-27 | The General Hospital Corporation | Photosensitizer conjugates for targeting intracellular pathogens |
EP1539212A4 (en) * | 2002-07-12 | 2007-05-02 | Medarex Inc | METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS |
-
2003
- 2003-12-09 KR KR1020117011747A patent/KR20110079741A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020157025001A patent/KR20150108943A/ko not_active Application Discontinuation
- 2003-12-09 NZ NZ541142A patent/NZ541142A/en not_active IP Right Cessation
- 2003-12-09 KR KR1020197008420A patent/KR20190034694A/ko not_active IP Right Cessation
- 2003-12-09 KR KR1020127011409A patent/KR20120068035A/ko not_active Application Discontinuation
- 2003-12-09 WO PCT/US2003/038941 patent/WO2004052401A2/en active Application Filing
- 2003-12-09 KR KR1020057010482A patent/KR20050095826A/ko not_active Application Discontinuation
- 2003-12-09 MX MXPA05006169A patent/MXPA05006169A/es unknown
- 2003-12-09 BR BR0317134-5A patent/BR0317134A/pt not_active Application Discontinuation
- 2003-12-09 PT PT03799876T patent/PT1585548T/pt unknown
- 2003-12-09 KR KR1020147033814A patent/KR20140148502A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020147003448A patent/KR20140027554A/ko not_active Application Discontinuation
- 2003-12-09 KR KR1020187024645A patent/KR20180098702A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20180098702A (ko) | 2018-09-04 |
KR20190034694A (ko) | 2019-04-02 |
WO2004052401A2 (en) | 2004-06-24 |
PT1585548T (pt) | 2018-10-17 |
KR20140027554A (ko) | 2014-03-06 |
KR20110079741A (ko) | 2011-07-07 |
NZ541142A (en) | 2008-07-31 |
KR20050095826A (ko) | 2005-10-04 |
KR20150108943A (ko) | 2015-09-30 |
KR20140148502A (ko) | 2014-12-31 |
MXPA05006169A (es) | 2006-03-30 |
WO2004052401A3 (en) | 2005-02-17 |
KR20120068035A (ko) | 2012-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0317134A (pt) | Composições e métodos de liberação de agentes farmacológicos | |
TR200502189T1 (tr) | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. | |
BR0109875A (pt) | Tratamento de doenças respiratórias | |
BR0307875A (pt) | Composição que pode ser administrada oralmente para a fotoproteção da pele | |
BR0307839A (pt) | Composição fotoprotetora para a pele que pode ser administrada por via oral | |
BR0015346A (pt) | Formulação farmacêutica contendo tolterodina e seu uso | |
NO2014016I1 (no) | Dimetylfumarat | |
BRPI0110914B8 (pt) | 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica' | |
BR9807577A (pt) | Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição | |
BR9914367A (pt) | Composições contendo ácidos difosfÈnicos | |
TW200603787A (en) | Topical preparations containing ambroxol | |
BR0014159A (pt) | Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional | |
BR9914419A (pt) | Terapia para melhoria da percepção | |
MX2007013137A (es) | Regimen anticonceptivo con dosificacion de estrogeno ampliada. | |
BR9912508A (pt) | Métodos e composições transdérmicas para alìvio da dor | |
BRPI0414500A (pt) | formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais | |
BR9909138A (pt) | Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda | |
BRPI0415713A (pt) | mio-inositol hexafosfato para uso tópico | |
BR9914631A (pt) | Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades | |
BR0014946A (pt) | Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina | |
BR9913135A (pt) | Formulação oral | |
BR9915861A (pt) | Composições tópicas contendo ascomicinas | |
BR0113148A (pt) | Composições de 2-piridinamina e métodos relacionados | |
BRPI0413404A (pt) | composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif | |
BRPI0410374A (pt) | composição farmacêutica que compreende valsartano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: AMERICAN PHARMACEUTICAL PARTNERS, INC. (US) Free format text: TRANSFERIDO POR FUSAO DE: AMERICAN BIOSCIENCE, INC. |
|
B25D | Requested change of name of applicant approved |
Owner name: ABRAXIS BIOSCIENCE, LLC (US) Free format text: ALTERADO DE: AMERICAN PHARMACEUTICAL PARTNERS, INC. |
|
B25A | Requested transfer of rights approved |
Owner name: ABRAXIS BIOSCIENCE, LLC (US) Free format text: TRANSFERIDO POR FUSAO DE :ABRAXIS BIOSCIENCE, INC. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 47/18; A61K 47/42; A61P 31/00 Ipc: A61K 47/18 (2011.01), A61K 47/42 (2011.01), A61P 3 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |